PHWR Public Health Weekly Report

Vol.15 No.15, April 14, 2022 Article TypeIssues on COVID-19 vaccinesNoncommunicable Disease StatisticsPolicy Notes

• Issues on COVID-19 vaccines 2022-04-14

  0 110 65

  Monitoring adverse events following initial vaccination with Novavax vaccine

  Insob Hwang, Hyungjun Kim, Sunyeong Seo, Yeon-Kyeng Lee, Yunhyung Kwon

  Public Health Weekly Report 2022; 15(15): 940-950

  

  

  Abstract

  Full Text Cite Share

  To investigate the incidence of adverse events following immunization (AEFIs) during the initial period of vaccination with Novavax, which has been in use in the Republic of Korea (ROK) since February 14, 2022, monitoring based on reports of adverse events reported by patients and guardians and active monitoring of adverse events after initial vaccination were conducted via mobile phone text messages and phone call surveys.
  The status of adverse events reports after vaccination until March 12, 2022 and the incidence of adverse events symptoms were monitored for 7 days after vaccination via text messages. The results of symptom manifestation and symptom intensity using phone call surveys on the third and seventh days after vaccination are presented, and the reporting rates of adverse events after vaccination with Novavax vaccine in the ROK was clarified.
  The reporting rate of adverse events was 193.9 per 100,000 vaccination, which was relatively lower than that for other coronavirus disease vaccines. The reporting rates of adverse events were similar in male and female and the rate was confirmed to decrease with increasing age. Monitoring via text messages and phone calls confirmed that the type and time of occurrence of adverse events to Novavax were similar to those of other existing vaccines, and the results were not significantly different from those confirmed in clinical trials.

• Policy Notes 2022-04-14

  0 128 97

  Introduction of a technical support system for new diagnostic tests of tuberculosis in the Republic of Korea

  Mee-Kyung Kee, Eunjin Cho, Jong Seok Lee, Seokyong Eum, Hyejon Lee, Sang Nae Cho

  Public Health Weekly Report 2022; 15(15): 959-968

  

  

  Abstract

  Full Text Cite Share

  Early diagnosis of tuberculosis (TB) patients and appropriate treatment are necessary to achieve Korea's national TB eradication goal of 40 per 100,000 by 2022 and 10 per 100,000 by 2030. We established a system that can objectively evaluate new TB diagnostic kits developed in the Republic of Korea (ROK) as well as evaluate useful diagnostic technologies that can be quickly adopted into TB control programs. For the evaluation of new TB diagnosis technologies, we formed an evaluation committee (New Tuberculosis Diagnostic Technology Evaluation Committee), has been secured clinical specimens by TB cohort study, operated TB biobanks, prepared reference materials for evaluation tests that can measure the usefulness of new technologies, and followed the Good Clinical Laboratory Practice for reliable evaluation tests. When the evaluation of new technology for TB diagnosis is requested by developers, the committee conducts a preliminary examination of the new TB diagnosis technology and decides whether to conduct an evaluation test or not. Following the step, an evaluation test plan, which includes the type of evaluation, test methods, the number of samples and repeated tests, etc., is prepared. The results of the evaluation test are then reported to the committee, and the committee conducts a comprehensive assessment of the results. The results of the comprehensive evaluation are classified into 4 categories (excellent, very good, average, and below-average), where results that are excellent and very good categories are recommended for further development and/or commercialization. Through the evaluation system, excellent new technologies for TB diagnosis can be discovered and continued to develop, or presented scientific evidence on necessary for the early utilization of diagnostic technology that can be applied in the field of TB control programs. In addition, new technology can serve as a bridgehead for entering global markets by promoting the development of new technologies for TB diagnosis developed in the ROK.

• Noncommunicable Disease Statistics 2022-04-14

  0 84 98

  Trends in the gap between metropolitan cities in walking 2011-2020

  Public Health Weekly Report 2022; 15(15): 969-970

  

  

  Full Text Cite Share